Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

sted after the close of the market on Monday, November 9, 2009 on the investor relations page of the Company's website.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, Adiana, AEG, BioLucent, Cervista, Cytyc, Eviva, MammoSite, MammoSite ML, MammoPad, NovaSure, R2, Selenia, Suros, ThinPrep and Third Wave and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:

This News Release contains forward-looking information that involves risks and uncertainties, including statements regarding the Company's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding: the expected continued market challenges; the Company's backlog and any implication that the Company's backlog may be indicative of future sales; the Company's expectations regarding product development and the performance of existing products; the Company's growth objectives; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- Commenting on GSK,s Q2 performance, the ... Dingemans reveals sales rose during the period and ... expectations. Ahead of a November R&D update day he ... The interview and transcript are available now on ... and webcasts with senior company executives. If you would ...
(Date:7/29/2015)... 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... development and commercialization of innovative therapies for the ... that it will release Second Quarter financial results ... AcelRx management will host an investment-community conference call ... Time) on Aug 3rd, 2015 to discuss the ...
(Date:7/29/2015)... NEW YORK and ... -- CMC Biologics, a global leader in clinical and ... Corporation (River Vision), a private company focused on ... an agreement for the process transfer and cGMP ... antibody targeting insulin-like growth factor 1 that is ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 2CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 3
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... subsidiary, Bayer Yakuhin, Ltd. ("Bayer Yakuhin"), and Santen ... EYLEA® (aflibercept) Injection in Japan.  As previously announced, ... authorization to the Ministry of Health, Labor and ...
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, medical and animal health practitioners, has been ranked ... Largest Corporations.  With net sales of $8.5 billion in 2011, ... the FORTUNE list in 2004 at number 487. ...
Cached Medicine Technology:Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 2Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 3Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 4Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 5Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 6Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan 7Henry Schein Ranks #303 In 2012 FORTUNE 500® Ranking Of America's Largest Corporations 2Henry Schein Ranks #303 In 2012 FORTUNE 500® Ranking Of America's Largest Corporations 3
(Date:7/29/2015)... ... ... Today marks a significant achievement in bringing new monies into early stage ... by a group of experienced investors, has tapped into an investor community passionate about ... a part of the fund. The Sofia Fund II is now closed to ...
(Date:7/29/2015)... ... ... July is National UV Awareness Month, and in honor of this month, Dr. Melda Isaac ... skin from the sun, as well as how to best treat existing sun damage. Sun ... common skin conditions in America. Many people do not protect their skin sufficiently when going ...
(Date:7/29/2015)... ... 29, 2015 , ... Stealth Therapeutics Inc. announced today that ... the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport product line, ... patient-friendly alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It ...
(Date:7/29/2015)... Toronto, Canada (PRWEB) , ... July 29, 2015 ... ... described as a “forward thinker.” Since the late 1970s, Dr. Cottrell has been ... His new book, The New Earth, documents many of these prognostications. He warns ...
(Date:7/29/2015)... ... July 29, 2015 , ... HealthPostures ( https://healthpostures.com ... partnership with 247Ergo, an ergonomics specialty firm. Purpose of the partnership is to ... companies undertake could improve worker mobility, functionality and fitness levels. , Executives ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 2Health News:July is UV Awareness Month: Learn Top Tips from a Prominent Dermatologist this National UV Awareness Month 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3
... been awarded a five-year, $2.1 million grant from the National ... study to assess blood flow and stroke risk. , Ischemic ... in the brain -- account for 80 percent of all ... They are often caused by atherosclerosis, a build-up of plaque ...
... Cap Health Care Conference at the Intercontinental The Barclay in New ... cap public and private health care companies in the following areas: ... Specialty Pharmaceuticals. , ... NEW YORK (Business Wire ...
... Best Practices in Vehicle Management, NEW ... was once again selected for its best ... in Wisconsin, Runzheimer,International provides a comprehensive range ... relocation, travel management, corporate,aircraft and virtual office ...
... BIHAR, India, Sept. 9 Entire villages have,been washed ... deadly,combination of monsoon rains and a dam burst caused ... IFAW (International Fund for Animal,Welfare -- http://www.ifaw.org ) ... has since treated and fed over 6000 starving livestock ...
... ... October 1, 2008, NEW YORK, ... children,s program "The Wumblers" to its schedule,of digital television broadcasts starting ... Network is a perfect,home for the cartoon series, whose audience spans ...
... R.I. Approximately one in four teens in the ... according to the Centers for Disease Control and Prevention. ... of many teens to use condoms consistently and routinely. ... of the factors that influence condom use among teenagers. ...
Cached Medicine News:Health News:UIC leads multi-center study to evaluate blood flow and stroke risk 2Health News:UIC leads multi-center study to evaluate blood flow and stroke risk 3Health News: Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector 2Health News: Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector 3Health News: Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector 4Health News: Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector 5Health News:The SCOOTER Store Recognized by Runzheimer International for Third Year 2Health News:Animal Rescue Operations Underway in Flooded Bihar, India 2Health News:Animal Rescue Operations Underway in Flooded Bihar, India 3Health News:Health Media Network Broadcasts 'The Wumblers' 2Health News:Teens' failure to use condoms linked to partner disapproval, fear of less sexual pleasure 2
SPR treats pigmented and vascular lesions, skin aging, sun damaged skin and fine lines and wrinkles with clinically proven LHE technology....
SkinStation, powered by LHE, is Radiancys flagship product. A powerhouse by design, it incorporates todays most sought after applications all on one user-friendly system ....
Inquire...
Inquire...
Medicine Products: